(Q44401122)

English

The Potent Somatostatin Analogue Vapreotide Does Not Decrease Pancreas-Specific Complications After Elective Pancreatectomy: A Prospective, Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial

scientific article published on April 1, 2003

In more languages
default for all languages
No label defined

No description defined

Statements

The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial (English)
The Potent Somatostatin Analogue Vapreotide Does Not Decrease Pancreas-Specific Complications After Elective Pancreatectomy: A Prospective, Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial (English)
556-64; discussion 564-5; author reply 565

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit